Jamieson Wellness 2B Takeover Bid|Canadas 1 Vitamin Brand Traded 30% Below Deal Value

Chapter 1: The Vitamin in Everyone's Cabinet Just Got a Takeover Offer

Jamieson Wellness, Canada's number-one vitamins and supplements brand, received an unsolicited offer to be acquired and its stock jumped nearly 14 percent to $43 a share — a level not seen since late 2020. The paradox is immediate: a company whose revenue more than doubled in five years, from roughly $400-million in 2020 to over $820-million in 2025, was trading at a valuation its own board apparently found cheap enough to accept a sale process. The bottleneck sits in the multiple — Jamieson's market price had been stuck at 10 to 11 times adjusted earnings before interest, taxes, depreciation and amortization, while comparable deals in the vitamins and supplements sector have consistently closed in the mid-teens. That gap is not a rounding error. It is the distance between a domestic consumer stock and a global health platform, and the board's decision to initiate a formal process on June 24 signals that management believes the market has been pricing the wrong thing. What remains unresolved is not whether Jamieson is worth more than the current share price implies — the comparable multiples answer that — but whether an unnamed bidder will bring an offer large enough to close the gap, or whether the process ends with no deal and a stock that retraces.

Chapter 2: The Gap the Market Ignored — 10× vs Mid-Teens

Royal Bank of Canada analyst Ryland Conrad stated plainly that Jamieson's valuation "has been largely stagnant" at 10 to 11 times EBITDA — below its own long-term average multiple of 13.5, and below the mid-teens multiples applied to comparable transactions. Each additional turn of EBITDA multiple equates to roughly $4.50 per Jamieson share, per Conrad's calculations. That means the difference between the current implied valuation and a 13.5-times deal is roughly $15 per share above where the stock was trading before the bid. At mid-teens — 15 times EBITDA — the gap widens further. The obvious counter-reading is that Jamieson's multiple was low for a reason: execution risk on its international expansion, a dollar-heavy acquisition in Youtheory at US$210-million in 2022, and a China operation that was still small when it was established. That counter-reading is now structurally weakened. Adjusted EBITDA rose from roughly $100-million in 2021 to nearly $160-million in 2025, and management projects 2026 EBITDA will surpass $174-million. The cash generation trajectory is no longer speculative. What the market had been treating as a forward promise has become a delivered result — yet the multiple never re-rated. The bid forces the question the market had been deferring: if the fundamentals have arrived, why was the stock still priced at 10 times?

Chapter 3: The China Engine — The Acquirer's Real Target

The answer to that question sits in China. Jamieson's Chinese revenue was less than $30-million in 2022. By 2025 it had reached $140-million, and the company is projecting at least $178-million for 2026 — growth that would make China Jamieson's second-largest market, behind only Canada. That trajectory is not incidental; it is the asset that a global vitamins and supplements acquirer would pay a premium to access. Nestle, Haleon — which makes Centrum — and Herbalife are among the potential strategic buyers named by analysts. Each would immediately recognize that Jamieson has done the hard part: it acquired its Chinese distribution partner's assets in 2022 rather than remaining dependent on a third party, which gave it direct control over pricing, shelf placement and brand positioning in a market where trust in supplement brands is a competitive moat. A private equity buyer, by contrast, would see the same China number as a multiple expansion story — buy at 11 times, restructure the cost base, exit at 14 or 15 times as China revenue compounds. The tension is that both buyer archetypes exist in this process simultaneously, and they have different ideas of what a fair price looks like. A strategic player can justify paying a higher multiple because Jamieson's China footprint accelerates their existing network. A financial buyer is more sensitive to the entry price. That bidder composition gap — strategic vs financial — is exactly what determines whether the eventual offer lands closer to $46, the RBC target, or whether it stretches into territory that makes the current $41 level look like a floor. What has not yet arrived is the actual number.

Chapter 4: The Only Number That Matters Now

The counter-evidence the pool carries is Jamieson's own language: "there can be no assurance that this process will result in any transaction." The board remains "committed to, and confident in, its current strategic plan" if no deal closes. That language is standard in Canadian M&A disclosure, but it is also a real risk vector — the process could end without a bid that meets the board's threshold, and a stock that ran 14 percent on rumour has room to retrace if the confirmed offer does not clear 13.5 times EBITDA. The read still leans toward a transaction completing. Jamieson hired BMO Capital Markets and Canaccord Genuity as advisors — a step that goes beyond acknowledging an inbound call and signals an active process with multiple parties. CEO Mike Pilato said in May that the company was "not desperate to do an acquisition" and had organic growth ahead; that posture suggests the board is not a distressed seller willing to accept the first number that arrives. The monitoring variable is the confirmed bid price per share relative to $46, which is RBC's fair-value target based on 13.5 times EBITDA. For the holder: if a formal offer comes in below $46 and the board signals resistance, the trade is to hold through the negotiation rather than sell at the opening bid. For the watch-list buyer: the entry setup confirms if the announced price clears 13.5 times EBITDA — that level would validate the comp-multiple thesis and signal that the process attracted strategic interest, not just financial buyers anchoring to a lower exit. The trap is the reverse: an offer at or below current market price, or a process termination, which sends the stock back toward pre-bid levels near $36. The confirmed bid price — not the share price movement — is the single fact that resolves this.